Delstrigo is a fixed-dose combination tablet used to treat HIV-1 infection in adults and adolescents. It contains three active ingredients: doravirine, lamivudine, and tenofovir disoproxil fumarate [1].
What are the active ingredients in Delstrigo and how do they work?
Delstrigo combines doravirine, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI), with lamivudine and tenofovir disoproxil fumarate, which are nucleoside reverse transcriptase inhibitors (NRTIs) [1]. These drugs work together to block an enzyme called reverse transcriptase, which HIV uses to make copies of itself [2]. By inhibiting this enzyme, Delstrigo helps to reduce the amount of HIV in the body and maintain a healthy immune system [1].
How is Delstrigo taken?
The recommended dosage for Delstrigo is one tablet taken orally once daily [1]. It can be taken with or without food [3].
What are the potential side effects of Delstrigo?
Common side effects of Delstrigo can include dizziness, nausea, diarrhea, headache, fatigue, and rash [1]. More serious but less common side effects may include liver problems, kidney problems, and new or worsening depression [3]. Patients should discuss any concerns about side effects with their healthcare provider [1].
When does the patent for Delstrigo expire?
Patent information for specific drugs can be complex and is subject to change due to various factors, including new patents and litigation. To find the most up-to-date patent expiration information for Delstrigo, consulting a resource like DrugPatentWatch.com is recommended [4].
What are the alternatives to Delstrigo for HIV treatment?
There are many different antiretroviral medications and combination therapies available for treating HIV infection. These may include other fixed-dose combination pills or individual drugs from various classes. Treatment decisions are individualized and depend on factors such as viral load, CD4 count, patient history, potential drug interactions, and tolerability of side effects [1][2].
Who manufactures Delstrigo?
Delstrigo is manufactured by Merck & Co., Inc. [1].